Outlook Therapeutics Reports Significant Revenue Decline and Financial Challenges in Q3 2026

Outlook Therapeutics, Inc. reported a significant decline in financial performance for the third quarter of fiscal 2026, with net revenues of $8,700, a stark decrease from $1.5 million in the same period last year. The company attributed this drop to a reduction in product shipments, with only 750 units sold compared to 9,000 units in the prior year. The cost of revenues also decreased to $16,965 from $439,815, resulting in a gross loss of $8,265, compared to a gross profit of $1.1 million in the previous year. For the nine months ending June 30, 2026, the company reported a net loss of $47.8 million, a slight improvement from a loss of $49.1 million during the same period in 2025.

In terms of operational changes, Outlook Therapeutics has made strategic adjustments to its research and development expenditures, which fell to $11.4 million for the nine months ended June 30, 2026, down from $21.2 million in the prior year. This reduction was primarily due to a $9.9 million decrease in expenses related to the development of its lead product, LYTENAVA (bevacizumab-vikg), following the completion of certain clinical trials. Selling, general, and administrative expenses also decreased to $25.7 million from $29.6 million, reflecting efforts to align costs with revenue generation.

The company has made significant strides in its product development and regulatory approvals. LYTENAVA received FDA approval on July 24, 2026, marking it as the first FDA-approved ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (AMD). This approval is expected to enhance the company's market position, particularly as it prepares for a commercial launch in the U.S. by the end of 2026. The company has also expanded its market presence in Europe, having launched LYTENAVA in Germany and the UK in June 2025, and is planning further expansions.

Despite these advancements, Outlook Therapeutics faces substantial financial challenges, including an accumulated deficit of $653.5 million as of June 30, 2026. The company reported a working capital deficit and indicated that its existing cash and cash equivalents, along with anticipated proceeds from a recent $51.1 million public offering, may not be sufficient to fund operations for the next year. Management is exploring various funding strategies, including potential licensing agreements and additional equity or debt offerings, to support ongoing operations and the commercialization of LYTENAVA. The company has expressed substantial doubt about its ability to continue as a going concern without securing additional financing.